MMN clinical trials at UCSF

1 research study open to eligible people

Multifocal motor neuropathy causes weakness in specific muscles because of nerve damage. UCSF is comparing a new antibody drug with standard IVIg in adults with MMN. UCSF is monitoring safety, strength, and daily function during the study.

Showing trials for

  • Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy

    open to eligible people ages 18 years and up

    The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months.

    San Francisco, California and other locations

Last updated: